The public record · 119th Congress

Expedited Access to Biosimilars Act

The Congressional Research Service has not published a summary of this measure.

Other titles

the names this measure carries besides the one at the top of this page, each with the record's own label for it. The collection includes titles given to parts of a bill as well as to the whole.

To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.Official Title as Introduced

Expedited Access to Biosimilars ActShort Title(s) as Introduced

Legislative history

H.R. 9661·House·Bill·Health

Rep. Nicholas A. Langworthy(Republican-New York-23)·

Jul 14, 2026

IntroducedIntroduced in House

Jul 14, 2026

HouseReferred to the House Committee on Energy and Commerce.

Documents

Everything Congress printed about this measure. A bill is reprinted each time it changes, the Congressional Research Service summarizes each version, and the committee that reports a bill files its own written account of it.

Bill text

Jul 14, 2026As introduced in the House